Graves'
Conditions
Interventions
The first group (full dose) received MMI at the same dose as before RAI,The second group (half dose) received MMI at half-dose before RAI. ,The last group (no dose) did not receive MMI after RAI.
Experimental Drug,Experimental Drug,Experimental No treatment
Full dose,Half dose,No dose
Sponsors
Siriraj Research Development Fund (managed by Routine to Research), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with Graves' disease were diagnosed by endocrinologists as having hyperthyroidism, diffused goiter without nodules, or serum thyroid autoantibodies that were positive. 2. Patients were followed up in the outpatient internal medicine clinic at Siriraj Hospital. 3. They had to be 18 or older. 4. Their free T3 and free T4 levels before RAI therapy had to be no higher than 2UNL. 5. They all had signs and symptoms that indicated RAI therapy.
Exclusion criteria
Exclusion criteria: 1. The patient who had Graves disease with a thyroid nodule. 2. Allergies to anti-thyroid medications. 3. Prior thyroid surgery. 4. Prior RAI therapy. 5. Psychiatric problems: Bipolar, Major depressive disorder, schizophrenia 6. Graves ophthalmopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The most appropriate MMI dosage to maintain euthyroid status after receiving RAI. 24 week after RAI therapy Median free T3 and free T4, duration of normal free T3 and free T4 levels (euthyroid status) in 3 patients groups | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life in Graves disease patients before and after receiving RAI therapy. Before and 24 weeks after AI therapy ThyPROth questionnaire | — |
Countries
Thailand
Contacts
Public ContactTada Kunavisarut
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed